UCSF home page About UCSF UCSF Medical Center
UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Decrease the text sizeRestore original text sizeIncrease the text size
Transporter Database banner  
Decrease the text size | Restore text size | Increase the text size
Text Sizer image
Home About and More Information Transporter Data Index
Search:  
 

SLC10A2

Synonyms: ASBT, IBAT, ISBT, NTCP2, PBAM

Entrez Gene Link

Expression Data
Substrate Information
Inhibitor Information
Clinical Drug-drug Interactions

Expression Data

Expression data for other tissues could be found in http://pharmacogenetics.ucsf.edu/gtex/index.html

Asterisk indicates important transporters in the organ as identified in the organ diagram.

Organ Source Relative Expression
Brain Nishimura    0.00000940
Kidney* Nishimura    0.0565
Liver Nishimura BLQ
Placenta Nishimura BLQ
Small Intestine* Nishimura    0.0902
Kidney* Mean across all PMT Samples    0.531
Liver Mean across all PMT Samples BLQ
Note that relative expression values should only be compared between entries of the same source.

Back to top

In Vitro Substrates

Substrate Km (μM) Cell System Reference
Cholate 33.3 COS1-ASBT Craddock, 1998
Glycochenodeoxycholate 5.7 COS1-ASBT Craddock, 1998
Glycodeoxycholate 2 COS1-ASBT Craddock, 1998
Glycoursodeoxycholate 4.1 COS1-ASBT Craddock, 1998
Taurocholate 13.3 COS1-ASBT Craddock, 1998
Taurocholate 16 COS-ASBT Love, 2001
Taurocholate 9.4 HEK-ASBT Hallen, 2002

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

In Vitro Inhibitors

Inhibitor IC50 (μM) Ki (μM) Substrate used Cell System Reference
Chenodeoxycholate 3.3 Taurocholate COS1-ASBT Craddock, 1998
Cholate 41.5 Taurocholate COS1-ASBT Craddock, 1998
Deoxycholate 6.3 Taurocholate COS1-ASBT Craddock, 1998
Taurochenodeoxycholate 6.1 Taurocholate COS1-ASBT Craddock, 1998
Taurodeoxycholate 17.2 Taurocholate COS1-ASBT Craddock, 1998
Tauroursodeoxycholate 28 Taurocholate COS1-ASBT Craddock, 1998
Ursodeoxycholate 75 Taurocholate COS1-ASBT Craddock, 1998

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

Clinical Drug-Drug Interactions

No drug-drug interaction information.


Back to top

Contact us | Glossary

Blue banner